Nuclear transcription factor Nrf2 suppresses prostate cancer cells growth and migration through upregulating ferroportin

Oncotarget

Volumn 7, Issue 48, 2016, Pages 78804-78812

  Xue, Dong ^a   Zhou, Cuixing ^a   Shi, Yunbo ^b   Lu, Hao ^a   Xu, Renfang ^a   He, Xiaozhou ^a  

^a SOOCHOW UNIVERSITY   (China)

^b CHANGZHOU INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Apoptosis; Ferritin; Ferroportin; Nrf2; Prostate cancer

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; FERRITIN; FERROPORTIN; TRANSCRIPTION FACTOR NRF2; CATION TRANSPORT PROTEIN; METAL TRANSPORTING PROTEIN 1; NFE2L2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL MIGRATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; MIGRATION INHIBITION; MITOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WOUND HEALING; CELL CYCLE CHECKPOINT; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CATION TRANSPORT PROTEINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FERRITINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MITOSIS; NEOPLASM INVASIVENESS; NF-E2-RELATED FACTOR 2; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84998799618     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12860     Document Type: Article

References (34)

1. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG and de Bono JS. Prostate cancer. Lancet. 2016; 387:70-82.
2. Dhawan M, Ryan CJ, Ashworth A. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. Oncologist. 2016.
3. Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell. 2015; 6:88-100.
4. Xue D, Zhou CX, Shi YB, Lu H, He XZ. Decreased expression of ferroportin in prostate cancer. Oncol Lett. 2015; 10:913-916.
5. Chen Y, Zhang Z, Yang K, Du J, Xu Y, Liu S. Myeloid zincfinger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene. 2015; 34:3839-3847.
6. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annual review of nutrition. 2006; 26:323-342.
7. Ornstein DL, Zacharski LR. Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. Nutr Cancer. 2007; 58: 115-126.
8. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306:2090-2093.
9. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000; 403:776-781.
10. Pan X, Lu Y, Cheng X, Wang J. Hepcidin and ferroportin expression in breast cancer tissue and serum and their relationship with anemia. Curr Oncol. 2016; 23:e24-26.
11. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010; 2:43ra56.
12. Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia. 2005; 7:109-117.
13. Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012; 1823:1426-1433.
14. Troadec MB, Ward DM, Lo E, Kaplan J, De Domenico I. Induction of FPN1 transcription by MTF-1 reveals a role for ferroportin in transition metal efflux. Blood. 2010; 116:4657-4664.
15. Taylor M, Qu A, Anderson ER, Matsubara T, Martin A, Gonzalez FJ, Shah YM. Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011; 140:2044-2055.
16. Marro S, Chiabrando D, Messana E, Stolte J, Turco E, Tolosano E, Muckenthaler MU. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position-7007 of the FPN1 promoter. Haematologica. 2010; 95:1261-1268.
17. Harada N, Kanayama M, Maruyama A, Yoshida A, Tazumi K, Hosoya T, Mimura J, Toki T, Maher JM, Yamamoto M, Itoh K. Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages. Arch Biochem Biophys. 2011; 508:101-109.
18. Frohlich DA, McCabe MT, Arnold RS, Day ML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene. 2008; 27:4353-4362.
19. Liu M, Yao XD, Li W, Geng J, Yan Y, Che JP, Xu YF, Zheng JH. Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal ROS levels. BioFactors. 2015; 41:52-57.
20. Chen Y, Zhang S, Wang X, Guo W, Wang L, Zhang D, Yuan L, Zhang Z, Xu Y, Liu S. Disordered signaling governing ferroportin transcription favors breast cancer growth. Cell Signal. 2015; 27:168-176.
21. Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). Int J Mol Med. 2007; 20:103-111.
22. Heath JL, Weiss JM, Lavau CP, Wechsler DS. Iron deprivation in cancer-potential therapeutic implications. Nutrients. 2013; 5:2836-2859.
23. Torti SV, Torti FM. Ironing out cancer. Cancer Res. 2011; 71:1511-1514.
24. Huang BW, Ray PD, Iwasaki K, Tsuji Y. Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4. FASEB journal. 2013; 27:3763-3774.
25. Nekhai S, Xu M, Foster A, Kasvosve I, Diaz S, Machado RF, Castro OL, Kato GJ, Taylor JGt and Gordeuk VR. Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. Haematologica. 2013; 98:455-463.
26. Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res Treat. 2013; 137:733-744.
27. Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013; 1836:245-254.
28. Zhou Y, Li Y, Ni HM, Ding WX, Zhong H. Nrf2 but not autophagy inhibition is associated with the survival of wildtype epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016; 310:140-149.
29. Lubelska K, Wiktorska K, Mielczarek L, Milczarek M, Zbroinska-Bregisz I, Chilmonczyk Z. Sulforaphane Regulates NFE2L2/Nrf2-Dependent Xenobiotic Metabolism Phase II, Phase III Enzymes Differently in Human Colorectal Cancer and Untransformed Epithelial Colon Cells. Nutr Cancer. 2016:1-11.
30. Kim EH, Jang HJ, Roh JL. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition. Mol Cancer Ther. 2016.
31. Schultz MA, Hagan SS, Datta A, Zhang Y, Freeman ML, Sikka SC, Abdel-Mageed AB, Mondal D. Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells. PloS one. 2014; 9:e87204.
32. Li W, Pung D, Su ZY, Guo Y, Zhang C, Yang AY, Zheng X, Du ZY, Zhang K, Kong AN. Epigenetics Reactivation of Nrf2 in Prostate TRAMP C1 Cells by Curcumin Analogue FN1. Chem Res Toxicol. 2016; 29:694-703.
33. Raatikainen S, Aaltomaa S, Karja V, Soini Y. Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy. Hum Pathol. 2014; 45: 2211-2217.
34. Sebastiani G, Wilkinson N, Pantopoulos K. Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Front Pharmacol. 2016; 7:160.